NEW YORK (GenomeWeb) – Foodborne pathogen molecular diagnostics firm Roka Bioscience has filed with the US Securities and Exchange Commission to go public.

In a preliminary prospectus filed on Wednesday, the firm said it plans to offer up to $75 million worth of shares in an initial public offering. It has not yet priced the offering or said how many shares it plans to sell. It expects to list on the Nasdaq Global Market under ticker symbol "ROKA."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.